Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement...
Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy,...
Genentech, a member of the Roche Group, announced new data from the Phase III IMbrave050 study that show Tecentriq plus Avastin demonstrated a statistically significant...
Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy...
Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), released preclinical data from the company’s portfolio of KIF18A inhibitors at...
